纤溶酶联合依达拉奉治疗进展性脑梗死的疗效观察

Study on the efficacy of fibrinogenase combined with edaravone on progressive cerebral infarction

目的观察纤溶酶联合依达拉奉治疗进展性脑梗死的疗效。方法将80例进展性脑梗死患者随机分为试验组(40例)及对照组(40例),两组均给与阿司匹林肠溶片、阿托伐他汀钙片治疗,试验组在此基础上给予纤溶酶联合依达拉奉注射液静脉滴注,14 d为1个疗程。结果试验组神经功能缺损评分在7、14 d时明显低于对照组(P<0.05)。结论纤溶酶联合依达拉奉治疗进展性脑梗死疗效显著。

Objective To observe the efficacy of fibrinogenase combined with edaravone on progressive cerebral infarction. Methods Eighty cases of progressive cerebral infarction patients were randomly divided into experimental group （40 cases） and control group （40 cases）. Two groups were both given aspirin, atorvastatin calcium tablets, and experimental group was additionally given fibrinogenase injection combined with edaravone injection for 14 days. Results Neurological deficit score of experimental group at 7 days, 14 days was significantly lower than that of control group （P 〈 0.05）. Conclusion The effi- cacy of fibrinogenase combined with edaravone on progressive cerebral infarction is remarkable.